FONT-SIZE Plus   Neg

Amarin Corp. (AMRN) Is Down Sharply On Vascepa Plans

Amarin Corp. (AMRN) announced a $100 million non-equity financing after the bell Thursday with an investment fund managed by Pharmakon Advisors. Amarin is continuing its preparations to commercialize Vascepa capsules with the hiring of a sales force in the United States.

Amarin gapped open sharply lower Friday morning and is now down 2.38 at $9.57 on above average volume. The stock has dropped to a 7 1/2 month low.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT